286 related articles for article (PubMed ID: 16239385)
21. [Biologics and cardiovascular risk].
Tarner IH; Müller-Ladner U; Hamm C
Z Rheumatol; 2010 Oct; 69(8):702-6, 708-11. PubMed ID: 20862482
[TBL] [Abstract][Full Text] [Related]
22. Therapy: A fine conception -- BSR/BHPR guidelines on drugs in pregnancy.
Sammaritano LR; Bermas BL
Nat Rev Rheumatol; 2016 Apr; 12(4):197-8. PubMed ID: 26984054
[TBL] [Abstract][Full Text] [Related]
23. European biologicals registers: methodology, selected results and perspectives.
Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
[TBL] [Abstract][Full Text] [Related]
24. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Strangfeld A; Hyrich K; Askling J; Arkema E; Davies R; Listing J; Neovius M; Simard J; Symmons D; Watson K; Zink A
Rheumatology (Oxford); 2011 Jan; 50(1):146-51. PubMed ID: 20861148
[TBL] [Abstract][Full Text] [Related]
25. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
26. How dangerous are norovirus infections in patients with rheumatic diseases treated with biologics and DMARDs? Follow-up on a local outbreak and comparison with a control cohort.
Fiehn C; Miehle N
Ann Rheum Dis; 2014 Apr; 73(4):786-7. PubMed ID: 24276367
[No Abstract] [Full Text] [Related]
27. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan.
Nakajima A; Saito K; Kojima T; Amano K; Yoshio T; Fukuda W; Inoue E; Taniguchi A; Momohara S; Minota S; Takeuchi T; Ishiguro N; Tanaka Y; Yamanaka H
Mod Rheumatol; 2013 Sep; 23(5):945-52. PubMed ID: 23073692
[TBL] [Abstract][Full Text] [Related]
28. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Mercer LK; Watson K; Packham J; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):80-85. PubMed ID: 30137485
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
Favalli EG; Caporali R; Sinigaglia L; Pipitone N; Miniati I; Montecucco C; Matucci-Cerinic M;
Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S15-27. PubMed ID: 21906424
[TBL] [Abstract][Full Text] [Related]
30. Infection risk and biologics: current update.
Wallis D
Curr Opin Rheumatol; 2014 Jul; 26(4):404-9. PubMed ID: 24827752
[TBL] [Abstract][Full Text] [Related]
31. The use of real-world data to address questions of patient safety.
Yates M; Bechman K; Galloway J
Rheumatology (Oxford); 2020 Jan; 59(1):26-30. PubMed ID: 31834407
[TBL] [Abstract][Full Text] [Related]
32. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
Flint J; Panchal S; Hurrell A; van de Venne M; Gayed M; Schreiber K; Arthanari S; Cunningham J; Flanders L; Moore L; Crossley A; Purushotham N; Desai A; Piper M; Nisar M; Khamashta M; Williams D; Gordon C; Giles I;
Rheumatology (Oxford); 2016 Sep; 55(9):1693-7. PubMed ID: 26750124
[No Abstract] [Full Text] [Related]
33. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
Palleria C; Iannone L; Leporini C; Citraro R; Manti A; Caminiti M; Gigliotti P; Grembiale RD; L'Andolina M; Muccari G; Naturale MD; Olivo D; Pagano Mariano G; Pellegrini R; Varcasia G; Abdalla K; Russo E; Ursini F; De Sarro G
PLoS One; 2018; 13(10):e0205134. PubMed ID: 30356301
[TBL] [Abstract][Full Text] [Related]
34. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
35. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Watson KD; Lunt M; ; Symmons DP;
Rheumatology (Oxford); 2011 Jul; 50(7):1341-2. PubMed ID: 21489973
[No Abstract] [Full Text] [Related]
36. Rheumatoid arthritis registries in Sweden.
van Vollenhoven RF; Askling J
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S195-200. PubMed ID: 16273807
[TBL] [Abstract][Full Text] [Related]
37. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
Wendling D; Di Martino V; Herbein G
J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
[No Abstract] [Full Text] [Related]
38. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register.
Symmons DP; Jones M; Osborne J; Sills J; Southwood TR; Woo P
J Rheumatol; 1996 Nov; 23(11):1975-80. PubMed ID: 8923378
[TBL] [Abstract][Full Text] [Related]
39. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
Marshall NJ; Wilson G; Lapworth K; Kay LJ
Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
[TBL] [Abstract][Full Text] [Related]
40. Malignancy and the Risks of Biologic Therapies: Current Status.
Seror R; Mariette X
Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
